When was Cellogen Therapeutics founded?

Cellogen Therapeutics was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Cellogen Therapeutics located?

Cellogen Therapeutics is headquartered in Noida, India. It is registered at Plot No. 06, 9th Floor, Magnus Tower, Sector 73, Sarfabad, Gautam Buddha Nagar, Dadri, Uttar Pradesh, India, 201307.

Which legal entities is Cellogen Therapeutics associated with?

Cellogen Therapeutics is associated with CELLOGEN THERAPEUTICS PRIVATE LIMITED.

Is Cellogen Therapeutics a funded company?

Cellogen Therapeutics is a funded company, having raised a total of $4.69M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 12, 2024.

How much is Cellogen Therapeutics worth?

The latest valuation of Cellogen Therapeutics is ₹***** as of May 16, 2026.

When was the latest funding round of Cellogen Therapeutics?

Cellogen Therapeutics' latest funding was a $***** Series A round on May 18, 2026, with participation from 2 investors. Its primary sector is Oncology. In India, the Oncology sector has seen $20M in funding in 2026 to date.

What is the annual revenue of Cellogen Therapeutics?

Annual revenue of Cellogen Therapeutics is less than ₹10 Cr as on Mar 31, 2025

Where does Cellogen Therapeutics rank among its competitors?

Cellogen Therapeutics ranks 969th amongst 3372 active competitors, of which 1145 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Cellogen Therapeutics?

Cellogen Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Cellogen Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Cellogen Therapeutics is a series A company based in Noida (India), founded in 2021 by Gaurav Kharya. It operates as a Developer of cellular engineering methods and gene therapy based treatments. Cellogen Therapeutics has raised $4.69M in funding from Natco Pharma, with a current valuation of ₹*****. The company has 3372 active competitors, including 1145 funded and 803 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of cellular engineering methods and gene therapy based treatments. Research focuses on creating therapies for hematological malignancies, solid tumors, and blood disorders. Activities include the design of antigen targeting therapies and the application of gene editing techniques to modify hematopoietic stem cells. These approaches aim to address the underlying causes of inherited and metabolic conditions through cellular manipulation.

Website: cellogentherapeutics.com
Social
Registered Address: Plot No. 06, 9th Floor, Magnus Tower, Sector 73, Sarfabad, Gautam Buddha Nagar, Dadri, Uttar Pradesh, India, 201307

Key Metrics

Founded Year

2021

Location

Noida, India

Stage

Series A

Total Funding

$4.69M in 3 rounds

Latest Funding Round

Series A, May 18, 2026, $*****

Post Money Valuation

₹***** as on May 16, 2026

Investors

Natco Pharma & 6 more

Ranked

969^th among 3372 active competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2025

Similar Companies

Jazz Pharmaceuticals & 3159 more

View Cellogen Therapeutics' full profile

Cellogen Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CELLOGEN THERAPEUTICS PRIVATE LIMITED CIN: U72100UP2021PTC202881 , India, Active	Jun 08, 2021	0 - ₹10 Cr (As on Mar 31, 2025)	-

Cellogen Therapeutics has raised a total funding of $4.69M over 3 rounds. Its first funding round was on Jan 12, 2024. Its latest funding round was a Series A round on May 18, 2026 for $*****. 2 investors participated in its latest round. Cellogen Therapeutics has 2 institutional investors and 5 angel investors.

Here is the list of recent funding rounds of Cellogen Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 18, 2026	6129346	Series A	3556836	8380779	4669982	6218812
Apr 25, 2025	9897123	Seed	5855265	2867252	2028417	1209540
Jan 12, 2024	4408018	Seed	7388011	6761261	Natco Pharma	1826873

Access funding benchmarks and valuations. Sign up today!

View details of Cellogen Therapeutics's funding rounds and investors

The founders of Cellogen Therapeutics is Gaurav Kharya.

Here are the details of Cellogen Therapeutics' key team members:

Gaurav Kharya: Founder of Cellogen Therapeutics. They are also an angel investor in 1 startup.

View details of Cellogen Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellogen Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Cellogen Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
969th	Cellogen Therapeutics 2021, Noida (India), Series A	Developer of cellular engineering methods and gene therapy based treatments	$4.69M	Natco Pharma, Kotak Alternate Asset Managers ... & 5 others	42/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Cellogen Therapeutics's competitors? Click here to see the top ones

Founders (largest shareholder) own 23.89%, Parent Entities own 22.01%, Enterprises own 5.38% and Angels own 1.07%. The net worth of Cellogen Therapeutics's founders is INR 66.7Cr as of Jul 22, 2025.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	23.89%	66.7Cr	3415535	4349662	7449299	7824926
Gaurav Kharya	3677427	7259435	9144544	2586688	6338121	4793861
Parent Entity	22.01%	61.4Cr	8346282	3812952	5564607	8318915
Enterprise	5.38%	15Cr	95433	67128	56532	52261
Angel	1.07%	3Cr	4	8	2	4
Other People	47.64%	133Cr	9776455	1204193	2950139	4654146
Total	100.00%	279Cr	5127432	8661246	7166284	3235886